Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform.

The company recognizes that no single technology can identify every cancer due to the inherent heterogeneity of the disease.

Freenome’s multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer’s subtlest cues, even at the earliest stages of disease.